Boston Scientific vs DexCom: Founders, CEOs and History
Boston Scientific was founded in 1979 by John Abele, Pete Nicholas and is led by Michael F. Mahoney. DexCom was founded in 1999 by Scott Glenn, Chuck Sherman and is led by Kevin Sayer.
Company facts
Boston Scientific
- Founded
- 1979
- Headquarters
- Marlborough, Massachusetts, United States
- Current CEO
- Michael F. Mahoney
- Employees
- 48,000
DexCom
- Founded
- 1999
- Headquarters
- San Diego, California
- Current CEO
- Kevin Sayer
- Employees
- 9,600
Founders
Boston Scientific
John Abele
John Abele co-founded the enterprise, establishing its foundational technology architecture and long-term operating vision.
Pete Nicholas
Pete Nicholas co-founded the enterprise, establishing its foundational technology architecture and long-term operating vision.
DexCom
Scott Glenn
Pioneering medical device entrepreneur who founded Dexcom in 1999 with a vision to eliminate fingerstick testing through continuous glucose monitoring.
Chuck Sherman
Key engineering pioneer who contributed to early electrochemical sensor design and foundational intellectual property.
CEOs and their tenures
DexCom
- Kevin Sayer
Chairman, President and CEO
- Jereme Sylvain
Executive Vice President and Chief Financial Officer
- Jake Leach
Executive Vice President and Chief Operating Officer
- Steven Pacelli
Executive Vice President, Strategy and Corporate Development
- Barry Regan
Executive Vice President, Global Operations
Timeline: Boston Scientific and DexCom side by side
1979Boston Scientific
Boston Scientific Founded
John Abele and Pete Nicholas establish Boston Scientific in Watertown, MA to pioneer less-invasive medical devices.
1992Boston Scientific
Initial Public Offering on NYSE
Lists on the New York Stock Exchange under ticker symbol BSX, raising capital for global expansion.
1995Boston Scientific
Acquisition of SCIMED Life Systems
Acquires SCIMED for $850M, establishing undisputed market leadership in interventional coronary angioplasty.
1999DexCom
Founded in San Diego
Dexcom founded in San Diego, California by Scott Glenn to revolutionize diabetes care.
2004Boston Scientific
Launch of Blockbuster TAXUS Stent
Introduces the TAXUS Express paclitaxel-eluting coronary stent, driving annual sales past $5 billion.
2006Boston Scientific
Landmark $27B Acquisition of Guidant
Acquires cardiac rhythm management leader Guidant, entering pacemakers, defibrillators, and heart failure devices.
2006DexCom
IPO & First FDA Approval
Completes initial public offering on NASDAQ under DXCM and receives FDA approval for first CGM.
2008DexCom
Dexcom SEVEN Launch
Introduction of the Dexcom SEVEN system, marking a significant leap in sensor longevity.
2011Boston Scientific
CE Mark for WATCHMAN Device
Receives European approval for the WATCHMAN left atrial appendage closure device for stroke prevention.
2012Boston Scientific
Michael F. Mahoney Appointed CEO
Michael Mahoney assumes leadership, initiating a comprehensive operational turnaround and portfolio revitalization.
2012DexCom
Dexcom G4 Platinum
Launch of the G4 Platinum, revolutionizing CGM accuracy and pediatric approval.
2015Boston Scientific
FDA Approval of WATCHMAN
Secures landmark FDA approval for WATCHMAN, launching commercial stroke prevention in US cardiac patients.
2015DexCom
Dexcom G5 Mobile
FDA approves G5 Mobile, the first CGM with mobile app connectivity without a receiver.
2018DexCom
G6 Launch & TypeZero Acquisition
Launch of Dexcom G6 featuring zero fingersticks and acquisition of TypeZero Technologies.
2019Boston Scientific
Acquisition of BTG for $4.2B
Expands into interventional oncology, vascular medicine, and specialized medical antidotes.
2019DexCom
$1.4B Revenue Milestone
Annual revenues surpass $1.4 billion as global patient adoption accelerates rapidly.
2020DexCom
Tandem Control-IQ Integration
Integration with Tandem Control-IQ automated insulin delivery closed-loop system.
2021Boston Scientific
Acquisition of Farapulse
Acquires Farapulse to secure the world's leading pulsed field ablation platform for cardiac arrhythmias.
2021DexCom
$2.4B Revenue Cross
Revenue crosses $2.4 billion with international expansion spanning over 90 countries.
2022DexCom
Dexcom G7 Clearance
FDA clearance of the Dexcom G7 featuring a 60% smaller footprint and 30-minute warm-up.
2023Boston Scientific
Acquisition of Relievant Medsystems
Adds the Intracept intraosseous nerve ablation system for vertebrogenic chronic low back pain.
2023DexCom
$3.62B Revenue Record
Annual revenues reach $3.62 billion with net income scaling to $541 million.
2024Boston Scientific
FDA Clearance of FARAPULSE PFA System
Secures historic FDA approval for FARAPULSE, transforming atrial fibrillation ablation across the US.
2024Boston Scientific
Acquisition of Axonics for $3.7B
Agrees to acquire Axonics to capture global market leadership in sacral neuromodulation for pelvic health.
2024Boston Scientific
Annual Revenue Reaches $14.2B
Achieves record financial performance with double-digit organic growth, serving 37 million patients worldwide.
2024DexCom
Stelo OTC Launch
Launch of Stelo, the first FDA-cleared over-the-counter biosensor for type 2 non-insulin diabetes.
2025DexCom
Global User Base Expansion
Global installed user base surpasses 2.5 million active diabetes patients worldwide.
2026DexCom
Next-Gen Multi-Analyte Biosensors
Advancement of multi-analyte biosensors and expanded automated pump partnerships.
2026DexCom
Manufacturing Scale-Up
Expansion of high-volume automated manufacturing facilities in Arizona and Malaysia.
2026DexCom
Market Cap Milestone
Market capitalization surpasses $32 billion amid robust institutional adoption.
Questions about Boston Scientific vs DexCom
Who is the CEO of Boston Scientific and DexCom, Inc.?
Boston Scientific is led by Michael F. Mahoney and DexCom, Inc. is led by Kevin Sayer. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Boston Scientific founded vs DexCom, Inc.?
Boston Scientific was founded in 1979 — 20 years before DexCom, Inc., which was founded in 1999. Boston Scientific's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger DexCom, Inc..
How many employees does Boston Scientific have compared to DexCom, Inc.?
Boston Scientific employs approximately 48,000 people, while DexCom, Inc. employs approximately 9,600. Boston Scientific has the larger workforce at 48,000 employees, compared to DexCom, Inc.'s 9,600. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Boston Scientific and DexCom, Inc. headquartered?
Both Boston Scientific and DexCom, Inc. are headquartered in United States. Their local rules and tax obligations may still differ.
Who founded Boston Scientific and DexCom, Inc.?
Boston Scientific was founded by John Abele, Pete Nicholas. DexCom, Inc. was founded by Scott Glenn, Chuck Sherman.
Which company has a longer operating history — Boston Scientific or DexCom, Inc.?
Boston Scientific has been operating for approximately 47 years, making it the more established of the two companies. DexCom, Inc. has been in operation for around 27 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Boston Scientific vs DexCom overview